ATP结合夹转录子A1研究进展

ATP结合夹转录子A1(ATP-bind ing cassette transporter A1,ABCA1)是1999年发现的极其重要的脂质转运蛋白,它是一种将过量胆固醇从细胞内向细胞外输送到载脂蛋白并包装成高密度脂蛋白(HDL)的膜蛋白。由于增加ABCA1的表达,可促进胆固醇的逆转运,减少了动脉粥样硬化的发生。该蛋白的研究是近年来脂代谢领域的研究热点。本文结合作者实验室近年来的研究以及国外的研究现状,从作用机制、蛋白调节、转基因模型、病理生理学意义等方面对ABCA1的研究进展进行概要介绍。     

三磷酸腺苷结合盒转运体A1研究的最新进展

就三磷酸腺苷结合盒转运体A1(ABCA1)的结构、功能及调控研究的最新进展作一综述.ABCA1是一种膜整合蛋白,它具有多种复杂的功能,能介导细胞内磷脂和胆固醇流出到贫脂载脂蛋白A-I,并且在高密度脂蛋白代谢过程中起重要作用.人类ABCA1变异将引起严重的高密度脂蛋白不足,其特征为载脂蛋白A-I和高密度脂蛋白缺陷以及动脉粥样硬化.ABCA1的表达受到多种物质高度调控.细胞核受体主要通过作用于ABCA1启动子DR4元件参与调节ABCA1表达.第二信使环磷酸腺苷通过作用于转录水平和翻译水平上调ABCA1表达.细胞因子对ABCA1转录具有多效性和矛盾效应.除此以外,各种蛋白质和酶类如蛋白激酶A,蛋白激酶CK2,组织蛋白酶D也参与ABCA1表达调控.     

ABCA1在动脉粥样硬化发生与发展中的作用

腺苷三磷酸结合盒转运体A1(ATP binding cassette transporter A1 ,ABCA1)是一种整合膜蛋白,它以ATP为能源,促进细胞内游离胆固醇和磷脂的流出,在胆固醇逆转运(RCT)和HDL生成的起始步骤中起重要作用,被称作RCT守门人。核受体PPARs、LXRs和FXR对ABCA1蛋白的表达具有调控作用。人体50种组织中存在有ABCA1 mRNA,在胰、肝、肺、肾上腺和胎儿组织中ABCAl表达水平最高,ABCAl功能障碍将导致巨噬细胞内大量的胆固醇沉积而成为泡沫细胞,继而漫润血管壁,促进As的发生发展。     

microRNAs——脂质代谢调控新机制

综述了近年来microRNAs,尤其是miR-33在脂质代谢调控方面的功能研究进展.脂质代谢在细胞水平进行有规律的调控,主要参与者有肝X受体(LXRs)和固醇调节元件结合蛋白(SREBPs)等.最近研究发现,非编码RNAs家族成员microRNAs在转录后水平调节脂质代谢相关基因表达,参与胆固醇、甘油三酯和脂肪酸代谢.其中miR-33可靶向沉默三磷酸脂苷结合盒(ABC)转运体家族成员ABCA1和ABCG1,抑制胆固醇流出和高密度脂蛋白(HDL)合成;通过靶向沉默脂肪酸β-氧化相关基因,如CPT1A、CROT和HADHB表达,抑制脂肪酸氧化;还可沉默AMPK和RIP140的表达,影响甘油三酯代谢.其他microRNAs如miR-122、miR-370、miR-125a-5p、miR-27、miR-320等,也参与调控胆固醇、甘油三脂、脂肪酸代谢及脂肪细胞分化.     

对氧磷降低RAW264.7巨噬细胞源性泡沫细胞ABCA1表达和胆固醇流出

三磷酸腺苷结合盒转运体A1(ABCA1)是体内胆固醇逆向转运的关键环节.对氧磷是广泛使用的有机磷农药的活性代谢产物.研究发现,对氧磷能增加巨噬细胞中胆固醇的堆积,但具体机制还不清楚.以RAW264.7巨噬细胞源性泡沫细胞为研究对象,观察对氧磷对RAW264.7巨噬细胞源性泡沫细胞ABCA1表达和胆固醇流出的影响并探讨其机制.结果显示,对氧磷以时间和剂量依赖的方式增加RAW264.7巨噬细胞源性泡沫细胞中总胆固醇、游离胆固醇和胆固醇酯水平,降低ABCA1表达和胆固醇流出,同时对氧磷降低细胞中环磷酸腺苷(cAMP)的水平及腺苷酸环化酶(AC)的活性和增加磷酸二酯酶(PDE)的活性,而cAMP的类似物双丁酰环腺苷酸(dBcAMP)能够阻断对氧磷降低ABCA1表达和部分阻断对氧磷降低胆固醇流出,对氧磷导致的cAMP水平的降低也可被AC激动剂福斯高林(Forskolin)和PDE抑制剂3-异丁基-1-甲基黄嘌呤(IBMX)所阻断.以上结果表明,对氧磷通过cAMP信号通路下调RAW264.7巨噬细胞源性泡沫细胞ABCA1的表达,降低细胞内胆固醇流出和增加细胞内胆固醇堆积.     

干扰素-γ对THP-1巨噬细胞源性泡沫细胞胆固醇流出和ABCA1表达的影响

以THP-1巨噬细胞源性泡沫细胞为研究对象,观察干扰素-γ(IFN-γ)对THP-1巨噬细胞源性泡沫细胞胆固醇流出和三磷酸腺苷结合盒转运体A1(ABCA1)表达的影响.以便探讨IFN-γ在动脉粥样硬化发生发展中的作用.采用液体闪烁计数器检测细胞内胆固醇流出, 高效液相色谱分析细胞内总胆固醇、游离胆固醇和胆固醇酯含量.运用逆转录-多聚酶链反应和蛋白质印迹分别检测ABCA1 mRNA与ABCA1蛋白质的表达, 采用流式细胞术检测细胞平均ABCA1荧光强度.发现IFN-γ引起THP-1巨噬细胞源性泡沫细胞总胆固醇、游离胆固醇与胆固醇酯呈时间依赖性增加, 而ABCA1 mRNA和蛋白质表达、细胞平均ABCA1荧光强度以及apoA-1介导的胆固醇流出呈时间依赖性减少, 细胞内胆固醇增多.结果表明IFN-γ抑制THP-1巨噬细胞源性泡沫细胞ABCA1表达及细胞内胆固醇流出,同时增加细胞内胆固醇聚积.     

肝细胞中活化转录因子ATF6抑制SREBP1的转录活性

内质网膜定位的活化转录因子ATF6和SREBP1均是经过蛋白酶切水解激活,激活后的ATF6(N)和SREBP1(N)进入细胞核内,分别指导内质网膜未折叠蛋白聚集反应相关基因和脂肪酸合成相关基因的表达.研究发现,肝细胞内葡萄糖饥饿激活ATF6并抑制SREBP1的转录活性及其靶基因的表达.过表达ATF6(N)能够抑制SREBP1介导的转录及其下游基因的表达.免疫共沉淀实验显示,ATF6(N)在细胞核内结合SREBP1(N),这种结合在无糖状况下增强.不同功能区缺失分析表明,ATF6和SREBP1通过亮氨酸拉链(leucinezipper)功能区相互作用.在葡萄糖饥饿状况下,ATF6对SREBP1转录活性的抑制保证了细胞基本生命活动所需要的能量.     

人肠组织特异抗原A33基因5′调控区的克隆及其功能分析

用基因组步行法 (genomewalker)克隆了人A33抗原基因的 5′调控区 94 0bp片段 ,并用PCR法鉴定了这一克隆的正确性 .将该序列提交GenBank ,登录号为AF2 0 0 6 2 6 .用引物延伸法 (primerex tension)确定了A33基因的转录起始位点 ,发现该位点位于一个TATA盒下游 10个碱基处 .以增强型绿色荧光蛋白为报告基因构建了不同长度的A33启动子 5′缺失载体 ,用脂质体介导的方法将这些载体转染LoVo、HeLa、2 93等细胞 ,比较了EGFP的表达水平 .研究发现 ,A33启动子上主要转录调控元件以及与组织特异性表达相关的转录调控元件位于A33启动子的 - 10 4～ + 2 5bp区域     

人肠组织特异抗原A33基因5′调控区的克隆及其功能分析

用基因组步行法 (genomewalker)克隆了人A33抗原基因的 5′调控区 94 0bp片段 ,并用PCR法鉴定了这一克隆的正确性 .将该序列提交GenBank ,登录号为AF2 0 0 6 2 6 .用引物延伸法 (primerex tension)确定了A33基因的转录起始位点 ,发现该位点位于一个TATA盒下游 10个碱基处 .以增强型绿色荧光蛋白为报告基因构建了不同长度的A33启动子 5′缺失载体 ,用脂质体介导的方法将这些载体转染LoVo、HeLa、2 93等细胞 ,比较了EGFP的表达水平 .研究发现 ,A33启动子上主要转录调控元件以及与组织特异性表达相关的转录调控元件位于A33启动子的 - 10 4～ + 2 5bp区域     

ABCA1的胞内运输及功能研究新进展

三磷酸腺苷结合盒转运体A1(ABCA1)具有介导细胞内脂质流出,维持细胞脂质稳态的功能．新生的ABCA1必须经过胞内运输和各种化学修饰等过程,最终成为具有功能的成熟转运体,才能行使其转运脂质的功能,因此,ABCA1在胞内的运输过程和正确质膜定位对其介导胆固醇流出的功能至关重要．目前ABCA1相关研究主要集中于脂质转运方面,并提出各种胆固醇流出机制的模型,如通道转运模型、蘑菇状突起模型和胞吞-胞吐转运模型等．最近研究显示,ABCA1还具有调节质膜脂筏结构、参与免疫和炎症调节等新功能．本文主要针对ABCA1的胞内运输过程以及各种功能做一综述,以期为动脉粥样硬化相关疾病提供新的治疗靶点和途径．     

ATP-binding cassette transporter A1 contains a novel C-terminal VFVNFA motif that is required for its cholesterol efflux and ApoA-I binding activities

The stimulation of cellular cholesterol and phospholipid efflux by apolipoprotein A-I is mediated by the activity of the ATP-binding cassette transporter A1 (ABCA1). Individuals with Tangier disease harbor loss-of-function mutations in this transporter that have proven useful in illuminating its activity. Here, we analyze a mutation that deletes the last 46 residues of the 2261 amino acid transporter (Delta46) and eliminates its lipid efflux. As the final four amino acids of the C terminus represent a putative PDZ-binding motif, we initially characterized deletion mutants lacking only these residues. Although a moderate decline in lipid efflux was detected, this decline was not as profound as that seen in the Delta46 mutant. Subsequent systematic analysis of the ABCA1 C terminus revealed a novel, highly conserved motif (VFVNFA) that was required for lipid efflux. Alteration of this motif, which is present in some but not all members of the ABCA family, did not prevent trafficking of the transporter to the plasma membrane but did eliminate its binding of apoA-I. Chimeric transporters, generated by substituting the C termini of either ABCA4 or ABCA7 for the endogenous terminus, demonstrated that ABCA1 could stimulate cholesterol efflux without its PDZ-binding motif but not without the VFVNFA motif. When a peptide containing the VFVNFA sequence was introduced into ABCA1-expressing cells, ABCA1-mediated lipid efflux was also markedly inhibited. These results indicate that the C-terminal VFVNFA motif of ABCA1 is essential for its lipid efflux activity. The data also suggest that this motif participates in novel protein-protein interactions that may be shared among members of the ABCA family.     

Quercetin enhances ABCA1 expression and cholesterol efflux through a p38-dependent pathway in macrophages

ATP-binding cassette transporter A1 (ABCA1) plays a crucial role in exporting cholesterol from macrophages, a function relevant to its involvement in the prevention of atherosclerosis. Quercetin, one of flavonoids, has been described to reduce atherosclerotic lesion formation. This study is aimed to investigate the effect of quercetin on regulation of ABCA1 expression and to explore its underlying mechanisms in macrophages. The results show that quercetin markedly enhanced cholesterol efflux from macrophages in a concentration-dependent manner, which was associated with an increase in ABCA1 mRNA and protein expression. Remarkably, quercetin is able to stimulate the phosphorylation of p38 by up to 234-fold at 6 h via an activation of the transforming growth factor β-activated kinase 1 (TAK1) and mitogen-activated kinase kinase 3/6 (MKK3/6). Inhibition of p38 with a pharmacological inhibitor or small hairpin RNA (shRNA) suppressed the stimulatory effects of quercetin on ABCA1 expression and cholesterol efflux. Moreover, knockdown of p38 reduced quercetin-enhanced ABCA1 promoter activity and the binding of specificity protein 1 (Sp1) and liver X receptor α (LXRα) to the ABCA1 promoter using chromatin immunoprecipitation assays. These findings provide evidence that p38 signaling is essential for the regulation of quercetin-induced ABCA1 expression and cholesterol efflux in macrophages.     

A novel function of apolipoprotein E: upregulation of ATP-binding cassette transporter A1 expression

Despite the well known importance of apolipoprotein (Apo) E in cholesterol efflux, the effect of ApoE on the expression of ATP-binding cassette transporter A1 (ABCA1) has never been investigated. The objective of this study was to determine the effect of ApoE on ApoB-carrying lipoprotein-induced expression of ABCA1, a protein that mediates cholesterol efflux. Our data demonstrate that ApoB-carrying lipoproteins obtained from both wild-type and ApoE knockout mice induced ApoAI-mediated cholesterol efflux in mouse macrophages, which was associated with an enhanced ABCA1 promoter activity, and an increased ABCA1 mRNA and protein expression. In addition, these lipoproteins increased the level of phosphorylated specificity protein 1 (Sp1) and the amount of Sp1 bound to the ABCA1 promoter. However, all these inductions were significantly diminished in cells treated with ApoE-free lipoproteins, when compared to those treated with wild-type lipoproteins. Enrichment with human ApoE3 reversed the reduced inducibility of ApoE-free lipoproteins. Moreover, we observed that inhibition of Sp1 DNA-binding by mithramycin A diminished ABCA1 expression and ApoAI-mediated cholesterol efflux induced by ApoB-carrying lipoproteins, and that mutation of the Sp1-binding motif in the ABCA1 promoter region diminished ApoB-carrying lipoprotein-induced ABCA1 promoter activity. Collectively, these data suggest that ApoE associated with ApoB-carrying lipoproteins has an upregulatory role on ABCA1 expression, and that induction of Sp1 phosphorylation is a mechanism by which ApoE upregulates ABCA1 expression.     

Enhanced cellular cholesterol efflux by naringenin is mediated through inhibiting endoplasmic reticulum stress - ATF6 activity in macrophages

Naringenin improves lipoprotein profile and protects against cardiovascular disease. ATF6 is an endoplasmic reticulum (ER) stress sensor with the same activation processes with sterol regulator SREBPs. Clinical data revealed that ATF6 expression was associated with plasma cholesterol level. Here, we investigated whether naringenin was involved in the regulation of cholesterol efflux and tested the role of ER stress-ATF6 in the naringenin function. Results showed that naringenin increased cholesterol efflux to both apoA-I and HDL and gene expressions in ABCA1, ABCG1 and LXRα in RAW264.7 macrophages. Naringenin inhibited the cleaved ATF6 nuclear translocation and its target GRP78 and XBP-1 expressions. Naringenin-induced cholesterol efflux was modulated by treatment with ER stress inhibitor 4-phenylbutyric acid, inducer tunicamycin and ATF6 overexpression in RAW264.7 and/or THP-1 cells, which suggested the naringenin functions were mediated through inhibiting ER stress-ATF6 pathway. Next, we found high-fat diet (HFD) supplemented with naringenin increased by >1.2-fold in cholesterol efflux capacity in primary peritoneal macrophage in apoE−/− mice compared to only HFD-fed mice. The increase was significantly reduced by tunicamycin treatment. Naringenin decreased GRP78, XBP-1 and nuclear ATF6 levels in peritoneal macrophage and aorta and reduced atherosclerotic lesion at aortic root, but reversed by tunicamycin. These confirmed participation of ER stress-ATF6 in naringenin efficacy. Finally, we found naringenin promoted AKT phosphorylation; PI3K inhibitor LY294002 treatment increased nuclear ATF6 and reduced naringenin-enhanced ABCA1 expression and cholesterol efflux. We concluded naringenin as a regulator for cholesterol efflux, and the regulation was mediated by ATF6 branch of ER stress and PI3K/AKT pathway.     

Sterol-responsive element-binding protein (SREBP) 2 down-regulates ATP-binding cassette transporter A1 in vascular endothelial cells: a novel role of SREBP in regulating cholesterol metabolism

ATP-binding cassette transporter A1 (ABCA1) is a pivotal regulator of cholesterol efflux from cells to apolipoproteins, whereas sterol-responsive element-binding protein 2 (SREBP2) is the key protein regulating cholesterol synthesis and uptake. We investigated the regulation of ABCA1 by SREBP2 in vascular endothelial cells (ECs). Our results showed that sterol depletion activated SREBP2 and increased its target, low density lipoprotein receptor mRNA, with a concurrent decrease in the ABCA1 mRNA. Transient transfection analysis revealed that sterol depletion decreased the ABCA1 promoter activity by 50%, but low density lipoprotein receptor promoter- and the sterol-responsive element-driven luciferase activities were increased. Overexpression of the N terminus of SREBP2 (SREBP2(N)), an active form of SREBP2, also inhibited the ABCA1 promoter activity. Functionally adenovirus-mediated SREBP2(N) expression increased cholesterol accumulation and decreased apoA-I-mediated cholesterol efflux. The conserved E-box motif was responsible for the SREBP2(N)-mediated inhibition since mutation of the E-box increased the basal activity of the ABCA1 promoter and abolished the inhibitory effect of SREBP2(N). Furthermore sterol depletion and SREBP2(N) overexpression induced the binding of SREBP2(N) to both consensus and ABCA1-specific E-box. Chromatin immunoprecipitation assay demonstrated that serum starvation enhanced the association of SREBP2 and the ABCA1 promoter in ECs. To correlate this mechanism pathophysiologically, we found that oscillatory flow caused the activation of SREBP2 and therefore attenuated ABCA1 promoter activity in ECs. Thus, this SREBP-regulated mechanism may control the efflux of cholesterol, which is a newly defined function of SREBP2 in ECs in addition to its role in cholesterol uptake and biosynthesis.